Cannabis at The Trump

trump-tower-november-2011The Trump Hotel in Toronto hosted a cannabis conference.

The Trump hosted a conference on cannabis. That’s how socially acceptable cannabis has become.

Sponsored by Jacob Securities and a host of marijuana-related companies, with InvestorIntel as the media sponsor, the one day conference on June 22, 2015 brought together the Licenced Producers, LP applicants, investors, stock exchanges (interesting speech from Richard Carleton of the Canadian Stock Exchange), those desperately seeking capital, and capital seeking a deal.

This feels like 1992 after the deregulation of the telecom industry, with hundreds of companies trying to find their niche in a wide-open undefined market. Valuations then, like today, weren’t based on any hard metrics but rather on, “we think we’re worth that because we said so”.

Wide-eyed true believers compete with jaded promoters to source capital in a nascent naive industry, and as the industry grows and those niches get filled, and as naivete gives way to experienced cynicism, the companies must evolve or die. As the CEO of Abba Medix Corp. Ray Rasouli (CSE:ABA) observed about the Licenced Producers, “Only the efficient firms will survive.”

Two themes were repeated throughout the day. First, every company strained to distinguish itself from the others. Second, everyone talked about, “a strategic client acquisition strategy”, a very difficult proposition when you can’t market to the end-user.

Terry Booth of Aurora Cannabis Inc. (CSE:ACB), whose main distinguishing factor is that it’s the only Licenced Producer in Alberta, provided an excellent overview of that company’s operations within the broader context of the regulatory environment. He made the pointed observation that Health Canada is not a proponent of marijuana in any form, but rather is a reluctant participant as directed by Canada’s courts. Patience and attention to detail are vital to surviving the application process.

Sometimes the distinguishing factor is a memorable soundbite. Organigram’s distinguishing factor is that it’s the only Licenced Producer east of Quebec. The Peace Natural Project was the first LP to have a bank account. Hydropothecary sets itself apart as targetting the luxury marijuana market (and having what could be the most unrealistic valuation).

The most popular man at today’s conference was Sasha Jacob, the conference’s main sponsor. A close second was Bill Fleming, CEO of Abattis Bioceuticals Corp. (CSE:ATT). This isn’t Bill’s first roll – he has extensive experience in the public markets. What makes Abattis unique is that it has capital and is ready to invest it. Based on a US$25 million equity line facility agreement with Dutchess Opportunity Fund, II, LP, Abattis is actively searching for intelligent cannabis-related investment opportunities. People trailed Bill like the tail of comet.

With the recent Smith Supreme Court of Canada decision permitting marijuana to be consumed in a format other than smoking, the consumables market could be ready to run. Many companies are looking to sell into this market as it develops.

The next two big events in this industry are the Allard decision from the Federal Court of Appeal, and the federal election in October, 2015. Both of these events will affect the “strategic client acquisition strategies”. While there may be a small rise in the run-up to the federal election, the market and the publicly traded shares will generally move sideways until those two events give direction.

Conferences like this one are vital to sharing ideas among the believers, the capital, the advisors, the regulators and the next generation of participants. They’re also key to shaping public sentiment about medical marijuana, legalized marijuana and hemp. The Trump hosting this conference shows how far that sentiment has come.

Abattis secures $25M funding from Dutchess Capital for cannabis M&A and development

Fleming-BillFebruary 19, 2015 — Tracy Weslosky, Publisher of InvestorIntel speaks to Bill Fleming, CEO and Director of Abattis Bioceuticals Corp. (“Abattis”) (CSE: ATT | OTCQX: ATTBF) on the recent US$25 million equity line facility agreement announcement with Dutchess Opportunity Fund, II, LP (“Dutchess”). Further discussions on Abattis initiatives towards investment, incubation and technology partnerships as a fully vertically integrated company in the rapidly expanding botanical drug and product development market.

Tracy Weslosky: : Thank you so much for joining us today and congratulations on your new role as CEO. And, of course, you had really big news last week $25 million dollar line of equity. Can you talk to us about that?

Bill Fleming: Absolutely. With Abattis we’re pretty excited about working with Dutchess. Dutchess is a global investment firm and we’ve been working with Dutchess now for the last few months to see how we can move forward with them on some of our initiatives. Again, it’s an equity line of credit and it’s something we have the ability to be able to tap into at the right time. Obviously, as we move forward our company we’re pretty excited some strategic opportunities that are out there and deal flow being one of them. That’s for sure.

Tracy Weslosky: Of course, all of the InvestorIntel audiences, I know a lot of us have been scratching our head on the cannabis and medicinal marijuana market. If you could just back us up and explain to our audience who Abattis Bioceuticals is.

Bill Fleming: Well, as a company today we’ve got many lines that from a product side, but we’re also involved in the investment. We’re involved in incubation. We’re involved with technology partnerships. We see ourselves as wanting to be a company that’s vertically integrated. As we move forward into certain areas we’re going to look at new technologies and new companies to either acquire or partner with on a go forward basis.

Tracy Weslosky: What does that mean for Abattis?

Bill Fleming: Well, what it means for Abattis is that we’ve actually got a good portfolio of companies. What we’re doing now is we’re looking at the realignment of some of these companies to make sure that there’s some synergies between them. Ultimately where we see ourselves moving as a company is that we want to move further up the food chain. We see ourselves as moving more into the botanical space. Botanical is what we call the new wave of pharmacy. We see ourselves differentiating ourselves and anyone else that’s out there because we have been pretty fortunate in finding some technologies, finding some great people, being able to work with some great financial partners. We foresee ourselves over the next few months as a company that’s going to be more strategically aligned to go after the cannabis industry.

Tracy Weslosky: So I received a lot of phone calls about your company when you received this $25 million dollar line with, who is this company and how did they manage to secure this. Can you talk to me a little bit about this? Does this have to do with management because you do have an impressive executive backgrounds?

Bill Fleming: A lot of it comes down to relationships. If I was going to give anybody credit it would have to be our chief operating officer, Rene David. Rene’s been the guy that’s been out there pounding the streets getting the Abattis message out there. Where we are today is basically as a result of his relationships. Obviously, Dutchess is a great company…to view the rest of the interview, click here

Disclaimer: Abattis Bioceuticals Corp. is an advertorial member of InvestorIntel.